bioAffinity Technologies, Inc.
BIAF
$0.4698
-$0.0292-5.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.26% | 687.40% | 12,071.07% | 267,277.78% | 96,134.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.26% | 687.40% | 12,071.07% | 267,277.78% | 96,134.78% |
| Cost of Revenue | -6.17% | 1,827.98% | 117,208.33% | 1,573,300.00% | 832,350.00% |
| Gross Profit | 17.67% | 306.70% | 5,250.81% | 104,025.00% | 24,831.82% |
| SG&A Expenses | 31.90% | 16.83% | 76.01% | 90.43% | 86.75% |
| Depreciation & Amortization | 3.23% | 162.67% | 599.54% | 589.40% | 1,938.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.13% | 66.77% | 149.46% | 179.15% | 180.17% |
| Operating Income | -25.79% | 13.97% | -17.40% | -24.85% | -44.26% |
| Income Before Tax | -25.14% | 12.68% | -21.28% | -28.74% | -41.58% |
| Income Tax Expenses | -100.00% | 13.04% | 17.39% | -68.64% | -- |
| Earnings from Continuing Operations | -25.02% | 12.66% | -21.27% | -27.99% | -41.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.02% | 12.66% | -21.27% | -27.99% | -41.72% |
| EBIT | -25.79% | 13.97% | -17.40% | -24.85% | -44.26% |
| EBITDA | -27.32% | 18.52% | -10.24% | -16.88% | -35.71% |
| EPS Basic | 21.09% | 38.69% | 9.26% | -8.92% | -27.67% |
| Normalized Basic EPS | 20.98% | 38.72% | 9.27% | -9.49% | -27.57% |
| EPS Diluted | 21.09% | 38.69% | 9.26% | -8.92% | -27.67% |
| Normalized Diluted EPS | 20.98% | 38.72% | 9.27% | -9.49% | -27.57% |
| Average Basic Shares Outstanding | 58.39% | 42.49% | 33.67% | 17.57% | 11.00% |
| Average Diluted Shares Outstanding | 58.39% | 42.49% | 33.67% | 17.57% | 11.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |